SENIOR LEADERSHIP
SENIOR LEADERSHIP
批准号:
7944855
负责人:
BRIAN LEYLAND-JONES
金额:
$16.83万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-07 至 2012-03-31
关键词:
American Cancer SocietyAntineoplastic AgentsAppointmentBiological MarkersBreast Cancer TreatmentBudgetsCanadaCancer CenterCancer Center Support GrantCenters for Disease Control and Prevention (U.S.)ClinicalClinical TrialsClinical Trials Cooperative GroupCollaborationsCommitCommittee MembershipCommunitiesComprehensive Cancer CenterDevelopmentDiseaseDoctor of PhilosophyEvaluationFacultyFoundationsGoalsHeadHealth SciencesIn VitroIndividualInstitutesInstitutionInvestigational DrugsLeadLeadershipMalignant NeoplasmsMedical OncologistMedicineMolecularNational Cancer InstituteOperative Surgical ProceduresPatient advocacyPharmacogeneticsPharmacologic SubstancePharmacologyPhasePhase III Clinical TrialsPhysiciansPopulation SciencesPositioning AttributePrincipal InvestigatorProtocols documentationPublic Health NursesPublic Health NursingQualifyingRecruitment ActivityResearchResourcesRoleScientistScreening procedureStagingStrategic PlanningStructureTechnologyTimeUniversitiesWorkadvocacy organizationsauthoritycancer therapychemotherapycollegeexperiencemedical schoolsmeetingsmultidisciplinarynoveloncologyprofessorprogramstherapy development
中文摘要
7.1温希普癌症研究所的高级领导
温希普癌症研究所所长兼美国癌症协会副会长
伍德拉夫健康科学中心:布莱恩·利兰-琼斯,医学博士
利兰-琼斯博士被任命为埃默里温希普癌症研究所(WCI)主任,
伍德拉夫健康科学中心(WHSC)副主任于2007年1月1日生效。
他完全有资格担任WCI主任。一位专门研究
乳腺癌治疗,拥有分子药理学博士学位,利兰-琼斯博士是一名
翻译内科医生-科学家,因其在个性化方面的工作而受到国际认可
癌症治疗和新的临床试验的发展。在他被任命之前,利兰博士-
琼斯是明达·德·冈兹伯格肿瘤学教授和麦吉尔大学医学教授
加拿大蒙特利尔的一所大学。1990年至2000年,他担任肿瘤学创始主席
麦吉尔大学综合癌症中心主任。1983-89年间,他是
年,研究药物处发育化疗科科长
癌症治疗,在国家癌症研究所。
利兰-琼斯博士在温希普癌症研究所领导工作的能力是
通过他之前的高级职位和作为高级翻译人员的经验来展示
科学家。在他担任麦吉尔综合癌症中心主任期间,
利兰-琼斯领导了一项临床试验业务的开发,该业务将研究与五项
临床试验合作小组和40多家制药公司。在他的领导下,
在利兰-琼斯的指导下,麦吉尔的癌症相关临床试验包括100多项
任何时候的方案,并通过九个多学科的疾病科室进行组织
在整个癌症中心。在NCI工作期间,他负责整个
近70种抗癌化合物的研究进展
三期临床试验的体外筛选。他在肿瘤临床药物遗传学方面的专长
L/11期抗癌药物的试验和生物标志物终点突显了他的卓越
领导WCI及其科学计划和共享这方面的核心资源的背景
寻求将NCI指定为癌症中心。
作为温希普癌症研究所所长,利兰-琼斯博士提供了总体
WCI的领导力、其科学计划、其共享的核心资源、其组织和
行政管理。利兰-琼斯博士代表WCI的战略规划和领导力
伍德拉夫健康科学中心内的委员会和医学院的
主席会议。署长的权力已在
上一节。利兰-琼斯博士控制着场地、设施、筹款的分配,
预算,以及Winship癌症研究所的其他资源。与个别部门联合
主席,他有能力为埃默里大学招聘新的教职员工,并拥有成员资格
委员会,他监督WCI的成员资格。作为矩阵中心的主任,利兰博士-
琼斯与医学院的其他院长和系主任密切互动,
伍德拉夫健康科学中心和埃默里学院的护理和公共卫生。他
还代表WCI与我们的社区合作伙伴合作,包括美国
癌症协会、疾控中心、佐治亚州癌症联盟、佐治亚州研究联盟、佐治亚州研究所
对于理工学院、莫尔豪斯医学院、GA-CORE和其他机构
乔治亚。利兰-琼斯博士提供与国家癌症研究所的接口,
国家和地方媒体,以及患者倡导组织和基金会。
利兰-琼斯博士全职担任WCI主任和校长
他是CCSG的调查员,但他的努力只有25%得到CCSG预算的支持。他会的
提供高级领导、监督、战略规划和持续的进度评估
争取在项目期间实现既定的目标和目的。
英文摘要
7.1 Senior Leadership of the Winship Cancer Institute
Director of the Winship Cancer Institute and Associate Vice-President for the
Woodruff Health Sciences Center: Brian Leyland-Jones, MD, PhD
Dr. Leyland-Jones was appointed Director of Emory's Winship Cancer Institute (WCI) and
Associate Director of the Woodruff Health Sciences Center (WHSC) effective January 1, 2007.
He is eminently well-qualified to serve as WCI Director. A Medical Oncologist who specializes in
breast cancer treatment, with a Ph.D. in Molecular Pharmacology, Dr. Leyland-Jones is a
translational physician-scientist who is internationally recognized for his work in individualized
cancer therapies and development of novel clinical trials. Prior to his appointment, Dr. Leyland-
Jones was the Minda de Gunzberg Chair in Oncology and Professor of Medicine at McGill
University in Montreal, Canada. From 1990 to 2000, he served as founding Chair of Oncology
and Director of the McGill University Comprehensive Cancer Centre. From 1983-89 he was
Head, Developmental Chemotherapy Section in the Investigational Drug Branch, Division of
Cancer Treatment, at the National Cancer Institute.
Dr. Leyland-Jones' capacity to lead the efforts at the Winship Cancer Institute is
demonstrated through his prior senior positions and experiences as a premier translational
scientist. During his tenure as Director of the McGill Comprehensive Cancer Centre, Dr.
Leyland-Jones led development of a clinical trials operation that integrated research with five
clinical trial cooperative groups and more than 40 pharmaceutical companies. Under Dr.
Leyland-Jones' direction, cancer-related clinical trials at McGill included more than 100
protocols at any one time and were structured through nine multidisciplinary disease sections
throughout the Cancer Centre. During his time with the NCI, he was responsible for the overall
development of approximately 70 anti-cancer compounds in various stages of transition from in
vitro screening to Phase III clinical trials. His expertise in pharmacogenetics in oncology clinical
trials and biomarker endpoints in Phase l/ll anti-cancer agents underscores his superb
background to lead the WCI and its scientific programs and shared core resources in this
pursuit of NCI designation as a cancer center.
In his role as Director of the Winship Cancer Institute, Dr. Leyland-Jones provides overall
leadership of the WCI, its scientific programs, its shared core resources, its organization, and its
administration. Dr. Leyland-Jones represents the WCI on strategic planning and leadership
committees within the Woodruff Health Sciences Center and on the School of Medicine's
Council of Chairs. The Authority of the Director is described in considerable detail in the
previous section. Dr. Leyland-Jones controls the space, facilities, allocation of fundraising,
budget, and other resources of the Winship Cancer Institute. Jointly with individual Department
Chairs, he has the ability to recruit new faculty to Emory University, and with the Membership
Committee he oversees membership in the WCI. As Director of a matrix Center, Dr. Leyland-
Jones interacts closely with other Deans and Department Chairs in the Schools of Medicine,
Nursing, and Public Health in the Woodruff Health Sciences Center and in Emory College. He
also represents the WCI in collaborations with our community partners, including the American
Cancer Society, CDC, Georgia Cancer Coalition, Georgia Research Alliance, Georgia Institute
for Technology, Morehouse School of Medicine, GA-CORE, and other institutions throughout
Georgia. Dr. Leyland-Jones provides the interface with the National Cancer Institute, with the
national and local media, and with patient advocacy organizations and foundations.
Dr. Leyland-Jones is committed full-time to his role as WCI Director and as Principal
Investigator for the CCSG, but only 25% of his effort is supported by the CCSG budget. He will
provide senior leadership, oversight, strategic planning, and on-going evaluation of progress
towards meeting established goals and objectives during the course of the project period.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Towards identification of prognostic gene sets in breast cancer: The E2197 Trial
-
批准号:8111749
-
项目类别:
-
资助金额:$16.29万
-
财政年份:2010
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
Towards identification of prognostic gene sets in breast cancer: The E2197 Trial
-
批准号:7878367
-
项目类别:
-
资助金额:$21.11万
-
财政年份:2010
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
CLINICAL TRIALS - PROTOCOL REVIEW MONITORING SYSTEM
-
批准号:7944911
-
项目类别:
-
资助金额:$7.98万
-
财政年份:2009
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
DATA SAFETY MONITORING PLAN
-
批准号:7944930
-
项目类别:
-
资助金额:$1.48万
-
财政年份:2009
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
PROGRAM PLANNING & EVALUATION
-
批准号:7944862
-
项目类别:
-
资助金额:$5.43万
-
财政年份:2009
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
DEVELOPMENTAL FUNDS
-
批准号:7944866
-
项目类别:
-
资助金额:$13.41万
-
财政年份:2009
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
CLINICAL TRIALS- PROTOCOL SPECIFIC
-
批准号:7944927
-
项目类别:
-
资助金额:$1.05万
-
财政年份:2009
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
Prognostic and predictive gene sets in HER2-positive breast cancer:The HERA Trial
-
批准号:7643722
-
项目类别:
-
资助金额:$21.41万
-
财政年份:2009
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
CANCER AND LEUKEMIA GROUP B
-
批准号:3557184
-
项目类别:
-
资助金额:$6.01万
-
财政年份:1982
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
SENIOR LEADERSHIP
-
批准号:8089515
-
项目类别:
-
资助金额:$18.36万
-
财政年份:--
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
CLINICAL TRIALS- PROTOCOL SPECIFIC
-
批准号:8089529
-
项目类别:
-
资助金额:$1.15万
-
财政年份:--
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
DEVELOPMENTAL FUNDS
-
批准号:8089518
-
项目类别:
-
资助金额:$15.57万
-
财政年份:--
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
PROGRAM PLANNING & EVALUATION
-
批准号:8089517
-
项目类别:
-
资助金额:$5.92万
-
财政年份:--
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
CLINICAL TRIALS - PROTOCOL REVIEW MONITORING SYSTEM
-
批准号:8089528
-
项目类别:
-
资助金额:$8.71万
-
财政年份:--
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
DATA SAFETY MONITORING PLAN
-
批准号:8089530
-
项目类别:
-
资助金额:$1.61万
-
财政年份:--
-
负责人:BRIAN LEYLAND-JONES
-
依托单位:
海外基金